The Quantellect read.As of Nov 19, 2026, 8 active firms cover Ardent Health Partners, Inc: 6 rate it Buy or better, 2 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets are tightly clustered, $11.00 to $14.00, so the covering firms are broadly aligned. The average target of $12.69 sits 12% below the current $14.38. Sentiment has drifted a little more constructive lately, with Sell ratings easing from 1 to 0 over recent months. On the fundamentals, the Street sees revenue growth near 4% this year and 5% next, consensus EPS building from about $0.31 next quarter toward $1.41 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS8 active firms
Buy
Strong Buy00%
Buy675%
Neutral225%
Sell00%
Strong Sell00%
Based on 8 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$12.69
-11.8% downside
Average target across 8 active firms as of Nov 19, 2026 vs $14.38 current
Highest Target$14.00
Average Target$12.69
Lowest Target$11.00
Detailed analyst forecasts for ARDT
Showing 1–8 of 8 named analysts shown · 8 active firms in the rating projection
As of Nov 19, 2026, 6 of 8 active firms rate ARDT a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
ARDT EPS & revenue forecast
EPS · NEXT QUARTER
$0.31
Range $0.27 – $0.36 · 4 analysts · +2% YoY
Next period, 4 analysts expect Ardent Health Partners, Inc. to earn $0.31 a share (range $0.27 – $0.36), versus $0.30 a year earlier. Full-year consensus is $1.32, growing to $1.41 the year after.
REVENUE · NEXT QUARTER
$1.6B
Range $1.6B – $1.7B · 4 analysts · +4% YoY
Revenue is expected to reach $1.6B (range $1.6B – $1.7B), +4.0% year-over-year. Full-year consensus is $6.5B, rising to $6.7B next year.
Top analysts covering Ardent Health Partners, Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ARDT.
#1
DM
David Macdonald
Truist Securities · Rank #111
Buy
No targeton ARDT
Overall win rate
50%
+ Follow
#2
Ben Hendrix
RBC Capital · Rank #150
Buy
$18.00+25.2% to target
Overall win rate
44%
+ Follow
#3
AR
A.J. Rice
UBS · Rank #365
Buy
$20.00+39.1% to target
Overall win rate
35%
+ Follow
#4
Craig Hettenbach
Morgan Stanley
Neutral
$13.50-6.1% to target
Coverage
—
+ Follow
#5
Jason Cassorla
Guggenheim
Buy
$14.00-2.6% to target
Coverage
—
+ Follow
ARDT stock forecast FAQ
What is ARDT's average 12-month price target?+
The 8 active firms with a live target average $12.69 for Ardent Health Partners, Inc. over the next 12 months, ranging from a $14.00 high to a $11.00 low, as of Nov 19, 2026.
Is ARDT stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 8 active firms as of Nov 19, 2026, 6 rate it Buy or Strong Buy, 2 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for ARDT?+
The Street-high target is $14.00 (Leerink Partners), and the Street-low is $11.00 (BMO Capital). The average of all 8 active-firm targets is $12.69.
How many active Wall Street firms cover ARDT?+
8 active firms have a recognized rating on Ardent Health Partners, Inc. as of Nov 19, 2026, and 8 active firms carry a live 12-month price target.
Who is the most accurate analyst covering ARDT?+
Among analysts who currently cover ARDT, David Macdonald of Truist Securities has the strongest overall Quantellect track record (Rank #111). Their current call is Buy.
What is Ardent Health Partners, Inc.'s projected EPS for next quarter?+
The consensus estimate is $0.31 per share (range $0.27 – $0.36) across 4 analysts. Full-year EPS is projected at $1.32, rising to $1.41 the following year.
How much revenue is Ardent Health Partners, Inc. expected to report next quarter?+
Consensus revenue is $1.6B (range $1.6B – $1.7B). Full-year revenue is projected at $6.5B, growing to $6.7B next year.
Have analysts been upgrading or downgrading ARDT lately?+
As of Nov 19, 2026, 6 of 8 active firms rate ARDT a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ARDT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.